Natalie R. Budilovsky-Kelley, PharmD

Director Medical Affairs
Braeburn

Poster(s):

• (266) Dosing to effect with weekly and monthly subcutaneous buprenorphine: post-hoc analysis of a Phase 3, open-label study
  Wednesday, October 29, 2025

• (267) Post-launch adverse events reported to FDA adverse event reporting system for long-acting injectable buprenorphine
  Wednesday, October 29, 2025